LVW Advisors LLC Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

LVW Advisors LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 949 shares of the medical research company’s stock after selling 56 shares during the period. LVW Advisors LLC’s holdings in Thermo Fisher Scientific were worth $552,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TMO. Gotham Asset Management LLC grew its position in Thermo Fisher Scientific by 47.5% in the 3rd quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock valued at $1,343,000 after acquiring an additional 855 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in Thermo Fisher Scientific by 54.3% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock valued at $6,128,000 after acquiring an additional 4,260 shares in the last quarter. Insigneo Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 26.9% during the third quarter. Insigneo Advisory Services LLC now owns 1,846 shares of the medical research company’s stock worth $935,000 after buying an additional 391 shares in the last quarter. Axxcess Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 51.6% during the third quarter. Axxcess Wealth Management LLC now owns 21,827 shares of the medical research company’s stock worth $11,048,000 after buying an additional 7,427 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of Thermo Fisher Scientific by 5.9% during the third quarter. Adage Capital Partners GP L.L.C. now owns 334,124 shares of the medical research company’s stock worth $169,124,000 after buying an additional 18,739 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TMO shares. Evercore ISI boosted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. HSBC upped their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $607.06.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock valued at $12,532,780 over the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $541.72 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The business has a 50 day simple moving average of $574.84 and a 200-day simple moving average of $563.36. The stock has a market capitalization of $206.79 billion, a PE ratio of 34.75, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.